eTable 5. Treatment outside the rehabilitation sector (complete cases).

Characteristics		IG (N = 211)		CG (N = 220)		p value
		Valid N	N (%)/M (SD)	Valid N	N (%)/M (SD)
Baseline data (T0)
Medication intakeduring the preceeding 3 months (yes)	5-aminosalicylates	211	114 (54.0%)	220	117 (53.2%)	0.860
	Corticosteroids		92 (43.6%)		92 (41.8%)	0.708
	Immunosuppressants		54 (25.6%)		61 (27.7%)	0.616
	Biologic agents		82 (38.9%)		84 (38.2%)	0.885
	None		6 (2.8%)		10 (4.5%)	0.350
Surgery for IBD	In the past 12 months (yes)	210	19 (9.1%)	219	19 (8.6%)	0.685
Hospital stay for IBD	In the past 12 months (yes)	211	71 (33.6%)	220	65 (29.5%)	0.359
Specialist visits for IBD in the past 12 months	N contacts overall	211	19.1 (16.0)	220	18.1 (16.4)	0.498
	N contacts gastroenterologist	204	5.8 (5.9)	209	6.1 (6.8)	0.619
Use of non-medical treatments/ counseling for IBD (past 12 months)	0	211	76 (36.0%)	219	78 (35.6%)	0.924
	1–2		92 (43.6%)		93 (42.5%)
	3+		43 (20.4%)		48 (21.9%)
Follow-up data (T1)
Medication intakeduring the preceeding 3 months (yes)	5-aminosalicylates	210	99 (47.1%)	218	99 (45.4%)	0.720
	Corticosteroids		58 (27.6%)		68 (31.2%)	0.417
	Immunosuppressants		39 (18.6%)		51 (23.4%)	0.221
	Biologic agents		88 (41.9%)		90 (41.3%)	0.896
	None		10 (4.8%)		14 (6.4%)	0.455
Surgery for IBD	Past 12 months (yes)	208	19 (9.1%)	217	12 (5.5%)	0.153
Hospital stay for IBD	Past 12 months (yes)	210	44 (21.0%)	217	41 (18.9%)	0.594
Specialist visits for IBD in the past 12 months	N contacts overall	210	16.8 (18.7)	220	16.7 (16.5)	0.938
	N contacts gastroenterologist	203	5.0 (5.5)	210	5.4 (6.0)	0.436
Use of non-medical treatments/ counseling for IBD (past 12 months)	0	211	88 (41.7%)	220	100 (45.5%)	0.728
	1–2		83 (39.3%)		82 (37.3%)
	3+		40 (19.0%)		38 (17.3%)

IBD, inflammatory bowel disease; IG, intervention group; CG, control group; M, mean; N, number of valid values; SD, standard deviation; T0, baseline; T1, follow-up